A vaccine shows promising results in treating the most deadly form of skin cancer, Moderna and Merck announced on Thursday. Those with severe melanomas who received the vaccine and Merck's cancer drug ...

New data from a trial of an investigational mRNA vaccine shows that it reduced the risk of recurrence of the serious skin cancer melanoma when combined with immunotherapy, according to drugmakers ...

Moderna stock jumped more than 24% Tuesday on upbeat results from a cancer treatment trial. The company reported its cancer vaccine combined with Keytruda reduced patients' risk by about 44%. Shares ...

A cancer vaccine developed by Moderna Inc. and Merck & Co. Inc. showed promising results in a key study, reducing the risk of recurrence or death by 44%, the drug makers said Sunday. About 79% of ...

An observational study of nearly half a million inoculated people found the Pfizer and Moderna COVID-19 vaccines had similar side effects, but the risk was lower in Moderna’s. Of the 433,762 veterans ...